Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Efficacy of Retapamulin Ointment, 1% Applied Twice Daily for 3 or 5 Days to the Anterior Nares of Healthy Adult Subjects Nasally Colonized With Staphylococcus Aureus

NCT00539994 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00539994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00539994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Efficacy of Retapamulin Ointment, 1% Applied Twice Daily for 3 or 5 Days to the Anterior Nares of Healthy Adult Subjects Nasally Colonized With Staphylococcus Aureus
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
January 31, 2008
Enrollment
57 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

infections, bacterial